CNSP
CNS Pharmaceuticals, Inc.
7.39
+0.12+1.7%
Dec 16, 4:00:01 PM EST

Upcoming Earnings 

Report date
≈ -/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap
4.58M
P/E (TTM)
0.01
Basic EPS (TTM)
776.03
Dividend Yield
0%

Recent Filings

About 

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.

CEO
Mr. John Michael Climaco Esq., J.D.
IPO
11/8/2019
Website
https://www.cnspharma.com
Employees
4
Sector
Healthcare
Industry
Biotechnology

Related Companies  

BZYR
Burzynski Research Institute, I
0.03-0.00
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CGTX
Cognition Therapeutics, Inc.
1.52-0.08
CING
Cingulate Inc.
3.87-0.28
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
CNTX
Context Therapeutics Inc.
1.10-0.03
CSBR
Champions Oncology, Inc.
6.73-1.14
NBTX
Nanobiotix S.A.
22.32+0.18
NRSN
NeuroSense Therapeutics Ltd.
0.85+0.01
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12